Here's Why You Should Add Glaukos Stock to Your Portfolio Now

Published on 9 Jan 2025 on Zacks · via Yahoo Finance

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results...

Read the rest of the article

Start tracking your investments with Statfolio

Glaukos Corporation GKOS reported fourth-quarter 2024 adjusted loss of 40 cents per share, narrow...

Zacks · via Yahoo Finance 21 Feb 2025

Key Insights The projected fair value for Glaukos is US$299 based on 2 Stage Free Cash Flow to...

Simply Wall St. · via Yahoo Finance 3 Feb 2025

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial result...

Zacks · via Yahoo Finance 9 Jan 2025

Shares of Glaukos Corporation GKOS scaled a new 52-week high of $155.76 on Jan. 6, before closing...

Zacks · via Yahoo Finance 7 Jan 2025

Glaukos Corporation GKOS recently announced that it has submitted its New Drug Application (NDA) ...

Zacks · via Yahoo Finance 24 Dec 2024

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial result...

Zacks · via Yahoo Finance 11 Dec 2024

GKOS stock gains from strong product demand, international expansion and pipeline progress, which...

Zacks · via Yahoo Finance 21 Nov 2024

Thursday, Glaukos Corporation GKOS reported a first-quarter adjusted EPS loss of $(0.70), up from...

Benzinga 3 May 2024

Glaukos Corporation GKOS reported first-quarter 2024 adjusted loss of 70 cents per share, which i...

Zacks via Yahoo Finance 3 May 2024

On Thursday, Glaukos Corporation (NYSE:GKOS) received an updated stock price target from Needham,...

Investing.com 3 May 2024